Salmedon

Salmedon is a biopharmaceutical company based in Leipzig, Germany, specializing in the discovery and development of novel small molecule inhibitors targeting the P2X7 receptor. The company's research focuses on the role of purinergic signaling in the NLRP3 inflammasome pathway, which is a critical driver of chronic inflammation and neurodegeneration. Salmedon's lead therapeutic candidates are designed to be highly selective and potent antagonists, aiming to provide new treatment options for patients with autoimmune and inflammatory disorders. Currently in the pre-clinical stage, the company is advancing its lead program, SAL-001, toward clinical development. Salmedon was founded as a spin-off from the University of Leipzig, leveraging deep expertise in medicinal chemistry and purinergic pharmacology.